MarketCap
Facebook
X
Telegram
Acorda Therapeutics DSO Ratio | ACOR
Annual DSO Ratio Acorda Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.3 | 47.5 | 52.6 | 50.4 | 43.2 | 277 | 41.5 | 29.4 | 23.6 | 28.6 | 31 | 29.3 | 28.2 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 277 | 23.6 | 56.2 |
Quarterly DSO Ratio Acorda Therapeutics
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.6 | 41.8 | 34.7 | 47.3 | - | 39.4 | 38.6 | 58.7 | - | 40 | 44.9 | 59.3 | - | 24.2 | 40.4 | 60.2 | 35.8 | 36.9 | 38 | 45.6 | 49.4 | 37 | 34.3 | 56.8 | 32.8 | 35.4 | 34.6 | 39.2 | - | 31.8 | 31.3 | 28.8 | - | 18.9 | 24.2 | 28.7 | - | 22.3 | 26.4 | 34 | - | 28 | 26.4 | 31.5 | - | 27.6 | 27.2 | 28.4 | - | 21.6 | 33 | 31.3 | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 60.2 | 18.9 | 36.1 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Kadmon Holdings, Inc.
KDMN
|
30.6 | - | - | $ 1.7 B |  USA |
 |
Liminal BioSciences
LMNL
|
429 | - | - | $ 256 M |  Canada |
 |
XBiotech
XBIT
|
40.8 | $ 1.97 | 3.2 % | $ 60.1 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
150 | - | -2.54 % | $ 57.2 M | USA |
 |
Osmotica Pharmaceuticals plc
OSMT
|
54.2 | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
0.0395 | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
365 | $ 1.76 | -2.09 % | $ 2.99 M | USA |
 |
Translate Bio, Inc.
TBIO
|
69.9 | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
2.34 K | - | - | $ 1.94 B | Canada |
 |
Acceleron Pharma Inc.
XLRN
|
42.2 | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
75.3 | - | 0.52 % | $ 821 M |  Danmark |
 |
Zogenix, Inc.
ZGNX
|
102 | - | -4.97 % | $ 664 M | USA |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
4.66 K | - | -7.58 % | $ 264 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
35.7 | $ 41.4 | 2.35 % | $ 3.28 B | Canada |
 |
Leap Therapeutics
LPTX
|
17.8 | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
211 | $ 31.45 | 2.08 % | $ 1.62 B | Canada |
 |
ADMA Biologics
ADMA
|
74.6 | $ 12.67 | -0.98 % | $ 3.02 B | USA |
 |
Daré Bioscience
DARE
|
877 | $ 0.69 | 1.75 % | $ 7.71 M | USA |
 |
Fate Therapeutics
FATE
|
122 | $ 1.78 | -8.51 % | $ 211 M | USA |
 |
Halozyme Therapeutics
HALO
|
93.4 | $ 103.0 | 0.08 % | $ 12.3 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
93.9 | $ 15.34 | 0.1 % | $ 13.2 B |  China |
 |
Aptorum Group Limited
APM
|
94 | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
138 | $ 0.78 | -1.89 % | $ 81.2 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
71.1 | $ 0.02 | -54.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M | Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
59.5 | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
88.7 | $ 25.32 | -3.78 % | $ 1.22 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
79.3 | $ 13.91 | 1.9 % | $ 1.24 B | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
6.94 K | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | - | - | $ 5.18 B | USA |